Needham keeps Buy rating on Liquidia with $58 price target
Needham reiterated its Buy rating on Liquidia shares with a $58 price target. Analysts point to the outlook for Yutrepia and the settlement with United Therapeutics.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Needham analysts kept their Buy rating on Liquidia (LQDA) shares and set a price target of $58 per share. According to Benzinga data, the stock closed at $26.81 on October 13, and the target implies an upside of 116.3% from that level.
The analyst note highlights Yutrepia as the main driver. Revised forecasts point to peak sales of $1.3 billion, and analysts see the product as promising for treating pulmonary arterial hypertension.
A recent settlement with United Therapeutics removed legal uncertainty around Yutrepia. This allows Liquidia to focus on widening the product's presence in the market and on additional clinical studies.
why it matters
Investors are weighing two points: the growth potential of a major product and the removal of legal risk. Analysts factor both into their view, but a price target alone is not a forecast of where the shares will trade. The Benzinga reference data is provided for information only and is not investment advice.
tags
instruments
sources
- Needham maintains Buy rating on Liquidia, $58 price target — Newsmetry API, 14 October 2026 at 10:11 UTC
- Rosenblatt maintains Buy rating on Imax, $65 price target — Newsmetry API, 14 October 2026 at 11:56 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗